Investigational Drug Details
| Drug ID: | D285 |
| Drug Name: | Proglumide |
| Synonyms: | Proglumide |
| Type: | Chemical drug |
| DrugBank ID: | DB13431 |
| DrugBank Description: | -- |
| PubChem ID: | 4922 |
| CasNo: | 6620-60-6 |
| Repositioning for NAFLD: | No |
| SMILES: | C(C(=O)N(CCC)CCC)(NC(=O)c1ccccc1)CCC(=O)O |
| Structure: |
|
| InChiKey: | DGMKFQYCZXERLX-UHFFFAOYSA-N |
| Molecular Weight: | 334.416 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | -- |
| Therapeutic Category: | Antiulcerative drug |
| Clinical Trial Progress: | Phase 1 on-going (NCT04152473) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0270 | NCT04152473 | Phase 1 | Active, not recruiting | No Results Available | December 13, 2019 | March 15, 2022 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00257 | 35163821 | Int J Mol Sci | Proglumide Reverses Nonalcoholic Steatohepatitis by Interaction with the Farnesoid X Receptor and Altering the Microbiome. | Details |
| A05792 | 33115780 | Cancer Prev Res (Phila) | Targeting the Cholecystokinin Receptor: A Novel Approach for Treatment and Prevention of Hepatocellular Cancer. | Details |
| A10536 | 31297627 | Dig Dis Sci | A Cholecystokinin Receptor Antagonist Halts Nonalcoholic Steatohepatitis and Prevents Hepatocellular Carcinoma. | Details |
| A51356 | 35336003 | Pharmaceutics | Safety and Pharmacokinetic Assessment of Oral Proglumide in Those with Hepatic Impairment. | Details |